BackTable / VI / Podcast / Episode #92

Interventional Oncology in Private Practice (Part 2)

with Dr. Justin Lee

Interventional Radiologist Justin Lee tells us about his approach to treatment of Hepatocellular Carcinoma (HCC), including how this has changed over his years in private practice. This is part two of a two part series.

Sponsored by:

TriSalus Life Sciences
Interventional Oncology in Private Practice (Part 2) with Dr. Justin Lee on the BackTable VI Podcast)
Ep 92 Interventional Oncology in Private Practice (Part 2) with Dr. Justin Lee
00:00 / 01:04

BackTable, LLC (Producer). (2020, October 29). Ep. 92 – Interventional Oncology in Private Practice (Part 2) [Audio podcast]. Retrieved from https://www.backtable.com

BackTable CMEfy button

Stay Up To Date

Follow:

Subscribe:

Sign Up:

Podcast Contributors

Dr. Justin Lee discusses Interventional Oncology in Private Practice (Part 2) on the BackTable 92 Podcast

Dr. Justin Lee

Dr. Justin Lee is a practicing interventional radiologist at Radiology Associates of Florida in Tampa, FL.

Dr. Christopher Beck discusses Interventional Oncology in Private Practice (Part 2) on the BackTable 92 Podcast

Dr. Christopher Beck

Dr. Chris Beck is a practicing interventional radiologist with Regional Radiology Group in New Orleans.

Show Notes

In this episode, Dr. Justin Lee joins Dr. Christopher Beck to discuss hepatocellular carcinoma (HCC) and interventional oncology in private practice. Dr. Lee tells us how he frames his HCC patients and works with medical oncologists for treatment plans and procedures.

We talk about the importance of IR bringing cases to the tumor board, the evolution of cases involving ablation, and why Dr. Lee started moving towards radioembolization (Y90). We review how to approach HCC cases while working with medical oncologists.

We examine the differences between using resin and glass for radioembolization and when they should be used. Dr. Lee shares why IR should start looking into arterial drug delivery for immunotherapies.

Resources

NEJM: Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
https://www.nejm.org/doi/10.1056/NEJMoa1915745
This paper, mentioned by Dr. Lee, discusses the third phase of an HCC trial.

Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Earn CME When You Listen to BackTable CMEfy

Up Next

Y90 in the OBL with Dr. Jayson Brower on the BackTable VI Podcast)
Building a Musculoskeletal Interventional Oncology Service with Dr. Alan Sag on the BackTable VI Podcast)
Cholecystostomy Tubes with Dr. Christopher Beck on the BackTable VI Podcast)
Microwave Ablation for Liver Lesions with Dr. Driss Raissi on the BackTable VI Podcast)
Discussing the Complications Survey Results with the BackTable Team on the BackTable VI Podcast)
New Tools to Treat Severe Distal Femoropopliteal Disease with Dr. John Rundback on the BackTable VI Podcast)

Articles

Topics

Hepatocellular Carcinoma Condition Overview
Learn about Interventional Oncology on BackTable VI
TACE Procedure Steps & Treatment
Y90 Radioembolization Procedure Prep

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

Select which show(s) you would like to subscribe to:

Thanks! Message sent.